Abeona Therapeutics Inc.
ABEO
$5.53
-$0.08-1.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.72M | 5.42M | -- | 400.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.72M | 5.42M | -- | 400.00K | -- |
| Cost of Revenue | 12.25M | 9.55M | 4.70M | 6.04M | 9.94M |
| Gross Profit | -3.53M | -4.13M | -4.70M | -5.64M | -9.94M |
| SG&A Expenses | 19.50M | 18.78M | 19.31M | 17.15M | 9.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.75M | 28.33M | 24.02M | 23.19M | 19.73M |
| Operating Income | -23.03M | -22.91M | -24.02M | -22.79M | -19.73M |
| Income Before Tax | -17.07M | -20.68M | -20.36M | 124.35M | -12.03M |
| Income Tax Expenses | 2.00K | -215.00K | -15.20M | 15.51M | -- |
| Earnings from Continuing Operations | -17.08M | -20.46M | -5.16M | 108.83M | -12.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.08M | -20.46M | -5.16M | 108.83M | -12.03M |
| EBIT | -23.03M | -22.91M | -24.02M | -22.79M | -19.73M |
| EBITDA | -22.34M | -22.05M | -23.41M | -22.25M | -19.19M |
| EPS Basic | -0.30 | -0.37 | -0.10 | 2.07 | -0.24 |
| Normalized Basic EPS | -0.19 | -0.23 | -0.23 | -0.33 | -0.15 |
| EPS Diluted | -0.30 | -0.37 | -0.10 | 1.71 | -0.24 |
| Normalized Diluted EPS | -0.19 | -0.23 | -0.23 | -0.26 | -0.15 |
| Average Basic Shares Outstanding | 56.62M | 55.22M | 54.24M | 52.52M | 49.78M |
| Average Diluted Shares Outstanding | 56.62M | 55.22M | 54.24M | 66.64M | 49.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |